Neurocrine Biosciences Inc generated $748.7M in free cash flow in fiscal year 2025. This represents an increase of 34.4% from the prior fiscal year. Over the trailing 12 months, Q3 FY2025 through Q2 FY2026, the same line adds up to $865.6M in free cash flow. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Neurocrine Biosciences Inc has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
NBIX Free Cash Flow by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
| Metric | TTM | FY2510-K | FY2410-K | FY2310-K | FY2210-K | FY2110-K | FY2010-K | FY1910-K | FY1810-K | FY1710-K | FY1610-K | FY1510-K | FY1410-K | FY1310-K | FY1210-K | FY1110-K |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | $865.6M | $748.7M+34.4% | $557.2M+54.1% | $361.6M+12.0% | $322.9M+38.5% | $233.1M+7.1% | $217.6M+64.5% | $132.3M+72.7% | $76.6M+175.6% | -$101.3M+8.2% | -$110.3M-176.2% | -$39.9M+18.1% | -$48.8M-61.7% | -$30.2M+16.9% | -$36.3M-2404.5% | -$1.4M |
TTM is the trailing twelve months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
NBIX Free Cash Flow by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What free cash flow means
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper.
More Neurocrine Biosciences Inc financials
Frequently Asked Questions
What was Neurocrine Biosciences Inc's free cash flow in fiscal year 2025?
Neurocrine Biosciences Inc generated $748.7M in free cash flow in fiscal year 2025.
How fast is Neurocrine Biosciences Inc's free cash flow growing?
Neurocrine Biosciences Inc (NBIX) free cash flow rose by 34.4% year over year, from $557.2M to $748.7M in fiscal year 2025.
What is Neurocrine Biosciences Inc's free cash flow over the last twelve months?
Neurocrine Biosciences Inc (NBIX) reported $865.6M in free cash flow over the trailing 12 months, Q3 FY2025 through Q2 FY2026, summed from the four most recent quarterly filings.
How has Neurocrine Biosciences Inc's free cash flow changed over the years?
Across the 15 fiscal years this page covers, Neurocrine Biosciences Inc (NBIX) free cash flow went from -$1.4M in fiscal year 2011 to $748.7M in fiscal year 2025.
What was Neurocrine Biosciences Inc's free cash flow in the most recent quarter?
Neurocrine Biosciences Inc (NBIX) reported $128.6M in free cash flow in Q2 2026. This represents an increase of 43.7% from the same quarter a year earlier.
What does free cash flow mean on a financial statement?
Free cash flow is the cash operations produced over the period, less what the company spent on property, plant and equipment, so it answers what was left over rather than what was earned on paper. This page lists what Neurocrine Biosciences Inc (NBIX) reported on that line in every period on record.